Financials in USD. Standardized financial statements.
A compact view of how Adaptimmune Therapeutics plc turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $178.03M | $60.28M | $27.15M | $6.15M | $3.96M | $1.12M | $59.51M | $37.83M | $14.20M | $10.72M |
| Revenue Growth? | +195.3% | +122.0% | +341.5% | +55.4% | +252.8% | -98.1% | +57.3% | +166.5% | +32.4% | 0.0% |
| Cost of Revenue? | $70,000 | $9.86M | $127.73M | $111.09M | $91.57M | $97.50M | $0 | $0 | $0 | $0 |
| Gross Profit? | $177.96M | $50.42M | -$100.58M | -$104.94M | -$87.61M | -$96.38M | $59.51M | $37.83M | $14.20M | $10.72M |
| Gross Margin? | +100.0% | +83.6% | -370.5% | -1706.6% | -2213.5% | -8589.9% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $246.72M | $188.42M | $191.11M | $168.40M | $137.36M | $140.89M | $141.87M | $118.49M | $87.00M | $33.79M |
| Operating Income? | -$68.76M | -$138.04M | -$163.97M | -$162.25M | -$133.41M | -$139.77M | -$82.36M | -$80.66M | -$72.80M | -$23.07M |
| EBITDA? | -$52.66M | -$128.20M | -$155.59M | -$155.68M | -$125.81M | -$131.76M | -$74.56M | -$75.24M | -$69.51M | -$23.77M |
| Income Before Tax | -$67.27M | -$112.53M | -$162.96M | -$157.30M | -$129.93M | -$136.92M | -$95.02M | -$69.69M | -$70.69M | -$23.69M |
| Income Tax Expense | $3.58M | $1.34M | $2.50M | $791,000 | $162,000 | $242,000 | $497,000 | $451,000 | $892,000 | -$2.11M |
| Net Income? | -$70.81M | -$113.87M | -$165.46M | -$158.09M | -$130.09M | -$137.16M | -$95.51M | -$70.14M | -$71.58M | -$21.59M |
| EPS? | $-0.28 | $-0.57 | $-1.02 | $-1.02 | $-0.90 | $-1.32 | $-0.96 | $-0.78 | $-1.02 | $-0.60 |
| Diluted EPS? | $-0.28 | $-0.57 | $-1.02 | $-1.02 | $-0.90 | $-1.32 | $-0.96 | $-0.78 | $-1.02 | $-0.60 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality